Iron isomaltoside 1000
Highest phase reached
Phase 3
Drug type
Unknown
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Unknown
- Drug name
- Iron isomaltoside 1000
- 1000 mg iron isomaltoside 1000
- 500 mg iron isomaltoside 1000
- diafer
- Diafer
- IRON (AS IRON(III) ISOMALTOSIDE 1000)
- iron as iron iii isomaltoside 1000
- iron isomaltoside (Monofer) intravenous infusion
- iron isomaltoside 1000
- Iron isomaltoside 1000
- Iron Isomaltoside 1000
- iron isomaltoside 1000 (Monofer®)
- Iron isomaltoside 1000 (Monofer®)
- Iron isomaltoside 1000 [WHO-DD]
- iron isomaltoside 1000 who dd
- iron isomaltoside(Monofer®)
- isofer
- Isofer
- jilazo
- Jilazo
- monofer
- Monofer
- MonoFer
- Monofer (experimental)
- Monofer (iron isomaltoside 1000)
- Monofer (isomaltoside)
And 2 more, listed on the interactive page.
- CAS registry numbers
- 1370654-58-2
- ChEMBL ID
- CHEMBL4298046
- FDA ingredient codes (UNII)
- 3M6325NY1R
- First in class
- No
- Orphan designation
- No
- Condition
- Inflammatory Bowel Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003767
- Subject identifier
- D015212
- Condition
- Renal Insufficiency, Chronic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003884
- Subject identifier
- D051436
- Condition
- Restless Legs Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004270
- Subject identifier
- D012148
- Condition
- Anemia
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004272
- Subject identifier
- D000740
- Condition
- Postpartum Hemorrhage
- Highest recorded phase
- 3
- Condition identifier
- EFO:0009579
- Subject identifier
- D006473
- Condition
- Anemia, Iron-Deficiency
- Highest recorded phase
- 3
- Condition identifier
- HP:0001891
- Subject identifier
- D018798
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition identifier
- EFO_0000266
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001070
- Condition identifier
- EFO_0002950
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003767
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003884
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003917
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003965
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004272
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009518
- Condition identifier
- EFO_0009579
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009909
- Condition identifier
- EFO_0020988
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001905
- Condition identifier
- HP_0001513
- Condition identifier
- HP_0001518
- Highest recorded phase
- 1
- Condition identifier
- HP_0001891
- Condition identifier
- HP_0001891
- Highest recorded phase
- 4
- Condition identifier
- HP_0002239
- Highest recorded phase
- 3
- Condition identifier
- HP_0012378
- Highest recorded phase
- 3
- Condition identifier
- HP_0012758
- Condition identifier
- MONDO_0000313
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0000565
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0001676
- Condition identifier
- MONDO_0002280
- Highest recorded phase
- 3
And 27 more, listed on the interactive page.
- Event
- abdominal pain
- Reports
- 59
- Reporting signal score
- 25.5861
- Event
- acute cardiac event
- Reports
- 1
- Reporting signal score
- 6.42987
- Event
- allergy to metals
- Reports
- 8
- Reporting signal score
- 35.1431
- Event
- anaphylactic reaction
- Reports
- 41
- Reporting signal score
- 42.4417
- Event
- autism spectrum disorder
- Reports
- 8
- Reporting signal score
- 23.2316
- Event
- back pain
- Reports
- 71
- Reporting signal score
- 55.2236
- Event
- blood iron decreased
- Reports
- 14
- Reporting signal score
- 28.8894
- Event
- bradycardia
- Reports
- 15
- Reporting signal score
- 33.443
- Event
- bradycardia foetal
- Reports
- 3
- Reporting signal score
- 14.2121
- Event
- caesarean section
- Reports
- 3
- Reporting signal score
- 6.64192
- Event
- cardiac arrest
- Reports
- 6
- Reporting signal score
- 12.7639
- Event
- chest crushing
- Reports
- 4
- Reporting signal score
- 23.5679
- Event
- chest discomfort
- Reports
- 58
- Reporting signal score
- 67.0768
- Event
- chest pain
- Reports
- 45
- Reporting signal score
- 20.4784
- Event
- crohn's disease
- Reports
- 24
- Reporting signal score
- 20.3672
- Event
- cyanosis
- Reports
- 5
- Reporting signal score
- 13.3438
- Event
- device interaction
- Reports
- 8
- Reporting signal score
- 36.2152
- Event
- discomfort
- Reports
- 4
- Reporting signal score
- 7.29231
- Event
- drug hypersensitivity
- Reports
- 91
- Reporting signal score
- 58.8923
- Event
- drug intolerance
- Reports
- 36
- Reporting signal score
- 21.6428
- Event
- dyspnoea
- Reports
- 150
- Reporting signal score
- 87.233
- Event
- faeces discoloured
- Reports
- 20
- Reporting signal score
- 31.9482
- Event
- fishbane reaction
- Reports
- 22
- Reporting signal score
- 150.59
- Event
- flushing
- Reports
- 64
- Reporting signal score
- 88.7504
- Event
- food allergy
- Reports
- 9
- Reporting signal score
- 20.1103
And 31 more, listed on the interactive page.
- NCT01017614
- NCT01213680
- NCT01599702
- NCT01213979
- NCT01213992
- NCT01222884
- NCT02940860
- NCT01280240
- NCT01895205
- NCT01895218
- NCT02172001
- NCT02940886
- NCT02962648
- NCT03237065
- NCT03238911
- NCT05251493
- NCT02484768
- Prodrug
- No
- Inorganic
- No
- Natural product
- No
Related records
Trials (362)
- "Predictive Models of the Morphological Evolution of the Human Body to Improve Adherence and Motivation in Dietetic-nutritional Treatments of Overweight and Obesity" [Modelos Predictivos de Evolución Corporal Para Mejorar la Adherencia en Tratamientos de Sobrepeso y Obesidad]
- 2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
- 3VM for Treatment of Chronic Osteoarthritis Knee Pain
- A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)
- A Clinical Study to Evaluate the Efficacy of a Cetylpyridinium Chloride Mouthwash in Improving Gingival Health and Reducing Plaque Accumulation
- A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors
- A Clinical Trial Evaluating the Monkeypox Recombinant Protein Vaccine
- A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants
- A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Umkamin Tab in Acute Bronchitis Patients
- A Clinical Trial to Evaluate the Safety and Efficacy of "AG1904" in Acute Bronchitis
- A Clinical Trial to Test the Effect of a Marketed Mouth Rinse on Stain Removal
- A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP
- A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer
- A Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis
- A First-in-Human Study With XAB05 in Healthy Subjects
- A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab
- A Multiple Ascending Dose Study of LW402 in Healthy Volunteers
- A Non-interventional Study of Diafer in Subjects With CKD on Haemodialysis for Treatment of Iron Deficiency
- A Pharmacokinetic Study of an Experimental Paracetamol Formulation
- A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
In development for (6)
- Anemia Phase 1
- Cancer Phase 1
- Chronic kidney disease Phase 3
- Inflammatory bowel disease Phase 3
- Iron deficiency anemia Phase 3
- Restless legs syndrome Phase 2